Late last weel week we've initiated coverage on Invitrocue, a Singapore-based company whose Onco-PDO technology is enabling personalised treatment solutions for cancer patients at low cost.
Invitrocue was founded in 2012 to commercialise two technologies for 3D cell culture, HepatoCue and 3D CelluSponge. These technologies are used to develop in vitro liver models to improve toxicology testing. Invitrocue also offers a clinical service called Onco-PDO, a tool for selecting the right drugs from an in vitro model of a patient’s tumour. Invitrocue is leveraging on its expertise and know-how in 3D cell culture to grow patient-derived cancer cells in its scaffolds and other platforms to test them against a range of cancer therapies. With Onco-PDO, the way is open for low-cost personalised cancer medicine, where the market opportunity lies in the billions. We value Invitrocue at 7.3 cents base case and 24.4 cents per share optimistic case. Our target price of 16 cents per share sits at the midpoint of our valuation range. We see Invitrocue being re-rated by further data showing the power of Onco-PDO, and the commencement of clinical studies to validate Onco-PDO ahead of regulatory approval.
You can download a copy of NDF Research's initiation report by clicking here or visiting ndfresearch.com. We commend the report to you. Note - the usual disclaimers apply - click here.